Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for rivaroxaban tablets, allowing the product to be marketed [1] Group 1: Product Approval - Rivaroxaban tablets are approved for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating and preventing deep vein thrombosis, treating pulmonary embolism, and preventing venous thromboembolism in acutely ill patients [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing of rivaroxaban tablets produced by its subsidiary, Changzhou Pharmaceutical Factory [1] Group 1: Product Information - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat and prevent deep vein thrombosis (DVT), treat pulmonary embolism (PE), and prevent venous thromboembolism (VTE) in acutely ill patients [1] - The drug was originally co-developed by BAYER and JANSSEN and was first launched in the United States in 2011 [1] Group 2: Regulatory Approvals - The rivaroxaban tablets received approval from the U.S. Food and Drug Administration (FDA) in May 2025 and obtained a drug registration certificate in Malaysia in October 2025 [1] Group 3: Investment and R&D - As of the date of the announcement, the company has invested approximately RMB 3.2482 million in research and development for the drug's market entry in Southeast Asia, including Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Health Sciences Authority of Singapore for the marketing of its rivaroxaban tablets, marking a significant step in expanding its overseas market presence [1][2]. Group 1: Product Approval and Market Impact - The rivaroxaban tablets are indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. - The approval in Singapore is part of a broader strategy to enter Southeast Asian markets, with additional investments of approximately RMB 3.2482 million allocated for research and development related to this product [1]. - The presence of other approved manufacturers in Singapore, including Bayer, Teva, and Intega, indicates a competitive landscape, with Bayer being the primary seller [1]. Group 2: Market Data and Future Prospects - The total sales value of rivaroxaban tablets in Singapore for the year 2024 is projected to be USD 8 million across three specifications (10mg, 15mg, 20mg) [1]. - The approval of rivaroxaban tablets in Singapore is expected to have a positive impact on the company's efforts to expand its overseas market and gain valuable experience [2].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於利伐沙班片獲得新加坡藥品註冊證書的公告》僅供 參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 2 月 25 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；職工董事為趙勇先生；以及獨立非執行董事為 顧朝陽先生、霍文遜先生、王忠先生及萬鈞女士。 证券代码：601607 证券 ...

证券代码：601607 证券简称：上海医药 编号：临2026-016 剂型：片剂 规格：10mg、15mg、20mg 注册分类：化学仿制药 申请事项：新产品上市 上海医药集团股份有限公司 关于利伐沙班片获得新加坡药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属常州制药厂有限公司（以下简称"常州制药厂"）生产的利伐沙班片（以下简 称"该药品"）收到新加坡食品药品监督管理局（HSA）颁发的药品注册证书， 该药品获得批准上市。 一、该药品基本情况 药品名称：利伐沙班片 1 号，并于 2025 年 10 月获得马来西亚药品注册证书。截至本公告日，公司针对该 药品在东南亚市场（即泰国、新加坡、马来西亚及菲律宾）上市另投入的研发费 用约人民币 324.82 万元。 三、该药品市场竞争情况 截至本公告日，在新加坡境内该药品主要有 BAYER，TEVA 和 INTEGA 等 其他 6 家获批厂商，BAYER 为主要销售商。 生产厂家：常州制药厂有限 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for the approval of rivaroxaban tablets for market launch [1] Group 1: Product Approval - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - The drug is also indicated for the treatment and prevention of deep vein thrombosis (DVT) [1] - Additionally, it is used for the treatment of pulmonary embolism (PE) and for the prevention of venous thromboembolism (VTE) in acutely ill patients [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a drug registration certificate from the Singapore Food and Drug Administration for the drug rivaroxaban, which has been approved for market launch [1] Group 1: Product Approval - The drug rivaroxaban is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - It is also indicated for the treatment and prevention of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) in acutely ill patients [1] Group 2: Investment and R&D - As of the announcement date, the company has invested approximately RMB 3.2482 million in research and development for this drug's market launch in Southeast Asia, specifically in Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals has announced the results of the third exercise period of its 2019 A-share stock option incentive plan, indicating that no stock options were exercised during this period [2][3][4]. Group 1: Stock Option Incentive Plan - The number of stock options available for exercise in the third period is 680,000, with the exercise period running from February 8, 2025, to February 7, 2026 [2]. - No stock options were exercised by the incentive recipients during the third exercise period [3]. - The unexercised stock options from the third exercise period will be canceled by the company [4]. Group 2: Approval Process for the Incentive Plan - The stock option incentive plan underwent several approval processes, including meetings of the board and supervisory board, and received approval from the Shanghai State-owned Assets Supervision and Administration Commission [5][6][7]. - The first grant of stock options was confirmed on December 19, 2019, with subsequent adjustments made to the list of incentive recipients and the number of options granted [10][11]. Group 3: Impact on Financials - As of the end of the third exercise period, the total share capital of the company is 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status or operating results [18].

Group 1: Board Election Announcement - The company announced the election of Mr. Zhao Yong as the employee representative director of the eighth board of directors, following the approval of the employee representative conference held on February 11, 2026 [1][3] - Mr. Zhao Yong meets the qualifications and conditions for the position as stipulated by relevant laws and the company's articles of association [1] - The number of directors who are also senior management and those who are employee representatives does not exceed half of the total number of directors, complying with legal requirements [1] Group 2: Stock Option Incentive Plan - The company reported that 680,000 stock options from the third exercise period of the 2019 A-share stock option incentive plan were available for exercise from February 8, 2025, to February 7, 2026 [5] - No stock options were exercised during the third exercise period, and the unexercised options will be canceled by the company [6][17] - The total share capital of the company as of the end of the third exercise period was 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status [22] Group 3: Approval of Raw Material Drug - The company announced that its subsidiary, Shanghai Pharmaceutical Kangli, received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride [23][24] - Tamsulosin hydrochloride is a third-generation selective long-acting α1 blocker used for treating benign prostatic hyperplasia (BPH) [25] - The company has invested approximately RMB 1.5 million in research and development for this drug, which is expected to enhance its market presence [26]

Group 1 - Unisplendour plans to raise no more than 5.57 billion yuan through a private placement to acquire a 6.98% stake in H3C and for other projects [1] - Dawi Technology's Zhangbei data center project will not involve computing power leasing and is expected to have minimal revenue contribution in 2025 [2] - Kaixin Network's subsidiary signed a settlement agreement with Legend IP, which is expected to positively impact the company's profit by approximately 200 million yuan [3] Group 2 - Newray plans to acquire a 70% stake in PCB tool company Huilian Electronics for no more than 700 million yuan, enhancing its market position [4] - Shangwei New Materials' embodied intelligent robot business is still in the product development stage and has not yet generated revenue [5] - Lanshi Heavy Industry's deputy general manager is under investigation for suspected violations, but the company's operations remain unaffected [6] Group 3 - Tianji Technology is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations, but its operations are normal [8] - Top Group expects a net profit decline of 3% to 13% in 2025, despite revenue growth of 8.08% to 14.10% [9] - Shoulu Hotel's subsidiary plans to invest 281 million yuan in a new hotel property project, expected to enhance its business scale and profitability [10] Group 4 - Pingzhi Information plans to raise no more than 1 billion yuan for the construction of a domestic intelligent computing center [11] - Dongfang Guoxin's Inner Mongolia intelligent computing center project has been partially completed, contributing a small revenue share [12] - Zhongwei Semiconductor intends to allocate 1 billion yuan of surplus fundraising for a new investment project [13] Group 5 - Guolin Technology plans to issue up to 16.5 million shares, which will increase its total share capital to 201 million shares [14] - Dabeinong reported a 22.71% year-on-year increase in pig sales in January [15] - Qiu Tai Technology sold 41.48 million mobile camera modules in January, a 19.5% year-on-year increase [19]